
John S. Kenyon
Examiner (ID: 15383, Phone: (571)270-1567 , Office: P/1625 )
| Most Active Art Unit | 1625 |
| Art Unit(s) | 1625, 1622 |
| Total Applications | 1218 |
| Issued Applications | 835 |
| Pending Applications | 153 |
| Abandoned Applications | 270 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 20445132
[patent_doc_number] => 20260001849
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2026-01-01
[patent_title] => NOVEL B0AT1 INHIBITOR
[patent_app_type] => utility
[patent_app_number] => 19/322058
[patent_app_country] => US
[patent_app_date] => 2025-09-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 53247
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 751
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19322058
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/322058 | NOVEL B0AT1 INHIBITOR | Sep 7, 2025 | Pending |
Array
(
[id] => 20100216
[patent_doc_number] => 20250230152
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-07-17
[patent_title] => PYRAZOLYL COMPOUNDS AS KV7 CHANNEL ACTIVATORS
[patent_app_type] => utility
[patent_app_number] => 19/097371
[patent_app_country] => US
[patent_app_date] => 2025-04-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26449
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19097371
[rel_patent_id] =>[rel_patent_doc_number] =>) 19/097371 | PYRAZOLYL COMPOUNDS AS KV7 CHANNEL ACTIVATORS | Mar 31, 2025 | Pending |
Array
(
[id] => 19862249
[patent_doc_number] => 20250101035
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-03-27
[patent_title] => CRYSTALLINE FORMS OF A MENIN INHIBITOR
[patent_app_type] => utility
[patent_app_number] => 18/827512
[patent_app_country] => US
[patent_app_date] => 2024-09-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9517
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 9
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18827512
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/827512 | Crystalline forms of a menin inhibitor | Sep 5, 2024 | Issued |
Array
(
[id] => 19940251
[patent_doc_number] => 12312373
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-05-27
[patent_title] => Cyclopropane skeleton monophosphine ligands, palladium complexes thereof, preparation methods and application
[patent_app_type] => utility
[patent_app_number] => 18/783334
[patent_app_country] => US
[patent_app_date] => 2024-07-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 4505
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 74
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18783334
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/783334 | Cyclopropane skeleton monophosphine ligands, palladium complexes thereof, preparation methods and application | Jul 23, 2024 | Issued |
Array
(
[id] => 20328363
[patent_doc_number] => 12458620
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-11-04
[patent_title] => Process for production of essentially pure D
[patent_app_type] => utility
[patent_app_number] => 18/765229
[patent_app_country] => US
[patent_app_date] => 2024-07-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 11
[patent_no_of_words] => 13587
[patent_no_of_claims] => 32
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 25
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18765229
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/765229 | Process for production of essentially pure D | Jul 5, 2024 | Issued |
Array
(
[id] => 19543086
[patent_doc_number] => 20240360122
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-31
[patent_title] => POLYMORPHIC FORMS AND SALTS OF A GLP-1R AGONIST
[patent_app_type] => utility
[patent_app_number] => 18/619638
[patent_app_country] => US
[patent_app_date] => 2024-03-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 82004
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18619638
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/619638 | POLYMORPHIC FORMS AND SALTS OF A GLP-1R AGONIST | Mar 27, 2024 | Pending |
Array
(
[id] => 19403578
[patent_doc_number] => 20240287089
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-29
[patent_title] => Preparation and Uses of 7-Azaindenoisoquinolines
[patent_app_type] => utility
[patent_app_number] => 18/618496
[patent_app_country] => US
[patent_app_date] => 2024-03-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29245
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 152
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18618496
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/618496 | Preparation and Uses of 7-Azaindenoisoquinolines | Mar 26, 2024 | Pending |
Array
(
[id] => 19785482
[patent_doc_number] => 20250059161
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-02-20
[patent_title] => COMPOUNDS AND METHODS FOR MODULATING STAT3
[patent_app_type] => utility
[patent_app_number] => 18/593361
[patent_app_country] => US
[patent_app_date] => 2024-03-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 119444
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18593361
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/593361 | COMPOUNDS AND METHODS FOR MODULATING STAT3 | Feb 29, 2024 | Pending |
Array
(
[id] => 20452987
[patent_doc_number] => 12516037
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-01-06
[patent_title] => Substituted thiophenecarboxamides and analogues as antibacterials agents
[patent_app_type] => utility
[patent_app_number] => 18/591732
[patent_app_country] => US
[patent_app_date] => 2024-02-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24103
[patent_no_of_claims] => 1
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 43
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18591732
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/591732 | Substituted thiophenecarboxamides and analogues as antibacterials agents | Feb 28, 2024 | Issued |
Array
(
[id] => 19389338
[patent_doc_number] => 20240279208
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-22
[patent_title] => Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamide
[patent_app_type] => utility
[patent_app_number] => 18/588874
[patent_app_country] => US
[patent_app_date] => 2024-02-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17586
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18588874
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/588874 | Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamide | Feb 26, 2024 | Pending |
Array
(
[id] => 19402103
[patent_doc_number] => 20240285614
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-29
[patent_title] => PHENOL RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/433734
[patent_app_country] => US
[patent_app_date] => 2024-02-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24698
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18433734
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/433734 | PHENOL RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF | Feb 5, 2024 | Pending |
Array
(
[id] => 19599450
[patent_doc_number] => 20240390330
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-28
[patent_title] => ALPHA-2-ADRENERGIC RECEPTOR AGONISTS FOR REDUCING REDNESS AND INCREASING WHITENESS IN EYES AND OTHER OPHTHALMIC PURPOSES
[patent_app_type] => utility
[patent_app_number] => 18/434505
[patent_app_country] => US
[patent_app_date] => 2024-02-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37657
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18434505
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/434505 | ALPHA-2-ADRENERGIC RECEPTOR AGONISTS FOR REDUCING REDNESS AND INCREASING WHITENESS IN EYES AND OTHER OPHTHALMIC PURPOSES | Feb 5, 2024 | Pending |
Array
(
[id] => 19210659
[patent_doc_number] => 11999707
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2024-06-04
[patent_title] => N'-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)-1-naphthimidamide as an antimicrobial compound
[patent_app_type] => utility
[patent_app_number] => 18/427924
[patent_app_country] => US
[patent_app_date] => 2024-01-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3965
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 31
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18427924
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/427924 | N'-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)-1-naphthimidamide as an antimicrobial compound | Jan 30, 2024 | Issued |
Array
(
[id] => 20451806
[patent_doc_number] => 12514849
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-01-06
[patent_title] => Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound
[patent_app_type] => utility
[patent_app_number] => 18/427477
[patent_app_country] => US
[patent_app_date] => 2024-01-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 3
[patent_no_of_words] => 7957
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 41
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18427477
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/427477 | Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound | Jan 29, 2024 | Issued |
Array
(
[id] => 19112726
[patent_doc_number] => 20240124476
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-18
[patent_title] => MOLECULAR CONTAINERS AND METHODS OF MAKING AND USING SAME
[patent_app_type] => utility
[patent_app_number] => 18/396432
[patent_app_country] => US
[patent_app_date] => 2023-12-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14167
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 148
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18396432
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/396432 | MOLECULAR CONTAINERS AND METHODS OF MAKING AND USING SAME | Dec 25, 2023 | Pending |
Array
(
[id] => 19151155
[patent_doc_number] => 11976051
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2024-05-07
[patent_title] => N'-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)-2-naphthimidamide as an antimicrobial compound
[patent_app_type] => utility
[patent_app_number] => 18/395377
[patent_app_country] => US
[patent_app_date] => 2023-12-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4056
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 25
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18395377
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/395377 | N'-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)-2-naphthimidamide as an antimicrobial compound | Dec 21, 2023 | Issued |
Array
(
[id] => 20634393
[patent_doc_number] => 12595260
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-04-07
[patent_title] => Stable heavy isotopes in amide functional groups and uses thereof
[patent_app_type] => utility
[patent_app_number] => 18/536859
[patent_app_country] => US
[patent_app_date] => 2023-12-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 9
[patent_no_of_words] => 20596
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 24
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18536859
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/536859 | STABLE HEAVY ISOTOPES IN AMIDE FUNCTIONAL GROUPS AND USES THEREOF | Dec 11, 2023 | Issued |
Array
(
[id] => 19359229
[patent_doc_number] => 20240261263
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-08
[patent_title] => COMPOUNDS AND METHODS TO SENSITIZE CANCER CELLS TO TYROSINE KINASE INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 18/530467
[patent_app_country] => US
[patent_app_date] => 2023-12-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11027
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 52
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18530467
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/530467 | COMPOUNDS AND METHODS TO SENSITIZE CANCER CELLS TO TYROSINE KINASE INHIBITORS | Dec 5, 2023 | Pending |
Array
(
[id] => 19048564
[patent_doc_number] => 20240090533
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-21
[patent_title] => METHODS AND FORMULATIONS FOR REDUCING BOVINE EMISSIONS
[patent_app_type] => utility
[patent_app_number] => 18/515987
[patent_app_country] => US
[patent_app_date] => 2023-11-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2734
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 21
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18515987
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/515987 | METHODS AND FORMULATIONS FOR REDUCING BOVINE EMISSIONS | Nov 20, 2023 | Pending |
Array
(
[id] => 19186190
[patent_doc_number] => 20240165103
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-23
[patent_title] => COMPOSITIONS AND METHODS FOR OPIOID ANTAGONIST DELIVERY
[patent_app_type] => utility
[patent_app_number] => 18/389356
[patent_app_country] => US
[patent_app_date] => 2023-11-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12098
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -2
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18389356
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/389356 | COMPOSITIONS AND METHODS FOR OPIOID ANTAGONIST DELIVERY | Nov 13, 2023 | Pending |